Rein Therapeutics (RNTX) Competitors

$1.13 -0.03 (-2.93%)

As of 09:54 AM Eastern

RNTX vs. EQ, CNTB, ACOG, IPHA, and AIFC

Should you buy Rein Therapeutics stock or one of its competitors? MarketBeat compares Rein Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rein Therapeutics include Equillium (EQ), Connect Biopharma (CNTB), Alpha Cognition (ACOG), Innate Pharma (IPHA), and ALT5 Sigma (AIFC). These companies are all part of the "pharmaceutical products" industry.

How does Rein Therapeutics compare to Equillium?

Rein Therapeutics (NASDAQ:RNTX) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Rein Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Equillium has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

Equillium has higher revenue and earnings than Rein Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.96	N/A
Equillium	$41.10M	3.45	-$22.40M	-$0.50	N/A

Equillium's return on equity of -119.19% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	-510.35%	-56.38%
Equillium	N/A	-119.19%	-93.79%

In the previous week, Equillium had 1 more articles in the media than Rein Therapeutics. MarketBeat recorded 5 mentions for Equillium and 4 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 0.63 beat Equillium's score of -0.28 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rein Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 5.1% of Rein Therapeutics shares are held by insiders. Comparatively, 17.8% of Equillium shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Rein Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 610.48%. Equillium has a consensus price target of $7.67, suggesting a potential upside of 242.26%. Given Rein Therapeutics' higher probable upside, research analysts clearly believe Rein Therapeutics is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Equillium	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Equillium beats Rein Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Rein Therapeutics compare to Connect Biopharma?

Connect Biopharma (NASDAQ:CNTB) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

Connect Biopharma has a beta of -0.21, indicating that its share price is 121% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

Rein Therapeutics has lower revenue, but higher earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,307.90	-$55.48M	-$1.00	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.96	N/A

Connect Biopharma's return on equity of -114.89% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-114.89%	-94.01%
Rein Therapeutics	N/A	-510.35%	-56.38%

In the previous week, Connect Biopharma had 9 more articles in the media than Rein Therapeutics. MarketBeat recorded 13 mentions for Connect Biopharma and 4 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 0.63 beat Connect Biopharma's score of -0.23 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rein Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 5.1% of Rein Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Connect Biopharma currently has a consensus price target of $8.67, indicating a potential upside of 253.74%. Rein Therapeutics has a consensus price target of $8.00, indicating a potential upside of 610.48%. Given Rein Therapeutics' higher possible upside, analysts plainly believe Rein Therapeutics is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Connect Biopharma beats Rein Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Rein Therapeutics compare to Alpha Cognition?

Rein Therapeutics (NASDAQ:RNTX) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

90.9% of Rein Therapeutics shares are owned by institutional investors. 5.1% of Rein Therapeutics shares are owned by company insiders. Comparatively, 14.0% of Alpha Cognition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rein Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 610.48%. Alpha Cognition has a consensus price target of $16.00, indicating a potential upside of 173.50%. Given Rein Therapeutics' higher possible upside, research analysts clearly believe Rein Therapeutics is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Alpha Cognition has higher revenue and earnings than Rein Therapeutics. Alpha Cognition is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.96	N/A
Alpha Cognition	$10.22M	12.46	-$20.67M	-$1.16	N/A

Rein Therapeutics has a net margin of 0.00% compared to Alpha Cognition's net margin of -202.23%. Alpha Cognition's return on equity of -55.71% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	-510.35%	-56.38%
Alpha Cognition	-202.23%	-55.71%	-43.78%

In the previous week, Rein Therapeutics had 3 more articles in the media than Alpha Cognition. MarketBeat recorded 4 mentions for Rein Therapeutics and 1 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 0.96 beat Rein Therapeutics' score of 0.63 indicating that Alpha Cognition is being referred to more favorably in the news media.

Company	Overall Sentiment
Rein Therapeutics	Positive
Alpha Cognition	Positive

Rein Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market.

Summary

Alpha Cognition beats Rein Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Rein Therapeutics compare to Innate Pharma?

Rein Therapeutics (NASDAQ:RNTX) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Rein Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 610.48%. Innate Pharma has a consensus price target of $5.00, indicating a potential upside of 189.02%. Given Rein Therapeutics' higher possible upside, research analysts clearly believe Rein Therapeutics is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 5.1% of Rein Therapeutics shares are owned by company insiders. Comparatively, 31.9% of Innate Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rein Therapeutics has higher earnings, but lower revenue than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.96	N/A
Innate Pharma	$10.19M	15.95	-$55.64M	N/A	N/A

Innate Pharma's return on equity of 0.00% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	-510.35%	-56.38%
Innate Pharma	N/A	N/A	N/A

In the previous week, Innate Pharma had 2 more articles in the media than Rein Therapeutics. MarketBeat recorded 6 mentions for Innate Pharma and 4 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 0.63 beat Innate Pharma's score of 0.58 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rein Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innate Pharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rein Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

Summary

Innate Pharma beats Rein Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Rein Therapeutics compare to ALT5 Sigma?

Rein Therapeutics (NASDAQ:RNTX) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Rein Therapeutics has higher earnings, but lower revenue than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.96	N/A
ALT5 Sigma	$24.84M	4.71	-$344.51M	N/A	N/A

Rein Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 610.48%. Given Rein Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Rein Therapeutics is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Rein Therapeutics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -1,386.90%. ALT5 Sigma's return on equity of -50.52% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	-510.35%	-56.38%
ALT5 Sigma	-1,386.90%	-50.52%	-45.05%

In the previous week, Rein Therapeutics had 1 more articles in the media than ALT5 Sigma. MarketBeat recorded 4 mentions for Rein Therapeutics and 3 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 1.08 beat Rein Therapeutics' score of 0.63 indicating that ALT5 Sigma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rein Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ALT5 Sigma	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are owned by institutional investors. 5.1% of Rein Therapeutics shares are owned by insiders. Comparatively, 0.2% of ALT5 Sigma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Rein Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market.

Summary

Rein Therapeutics beats ALT5 Sigma on 8 of the 13 factors compared between the two stocks.

Get Rein Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNTX vs. The Competition

Export

Metric	Rein Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$31.57M	$3.42B	$6.31B	$12.29B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-0.57	18.67	21.03	25.62
Price / Sales	N/A	297.38	551.42	75.98
Price / Cash	19.59	122.51	42.94	55.34
Price / Book	-1.05	6.75	9.76	6.66
Net Income	-$49.87M	$24.11M	$3.55B	$333.63M
7 Day Performance	-3.76%	-0.53%	-0.53%	-0.12%
1 Month Performance	-30.92%	0.34%	1.20%	3.93%
1 Year Performance	-49.96%	78.62%	41.21%	36.07%

Rein Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNTX Rein Therapeutics	3.2795 of 5 stars	$1.13 -2.9%	$8.00 +610.5%	-40.8%	$31.57M	N/A	N/A	9	News Coverage Short Interest Increase
EQ Equillium	2.5785 of 5 stars	$2.11 flat	$7.67 +263.3%	+504.6%	$133.42M	$41.10M	N/A	40	Positive News Earnings Report
CNTB Connect Biopharma	2.9708 of 5 stars	$2.36 flat	$8.67 +267.2%	+221.9%	$133.39M	$60K	N/A	110	Earnings Report Upcoming Earnings Analyst Revision Gap Down
ACOG Alpha Cognition	3.4262 of 5 stars	$6.10 flat	$16.00 +162.3%	-13.9%	$132.80M	$10.22M	N/A	N/A
IPHA Innate Pharma	3.1539 of 5 stars	$1.41 flat	$5.00 +254.6%	-35.3%	$132.43M	$10.19M	N/A	220	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNTX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rein Therapeutics (RNTX) Competitors

RNTX vs. EQ, CNTB, ACOG, IPHA, and AIFC

How does Rein Therapeutics compare to Equillium?

Summary

How does Rein Therapeutics compare to Connect Biopharma?

Summary

How does Rein Therapeutics compare to Alpha Cognition?

Summary

How does Rein Therapeutics compare to Innate Pharma?

Summary

How does Rein Therapeutics compare to ALT5 Sigma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX vs. The Competition

Rein Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rein Therapeutics (RNTX) Competitors

RNTX vs. EQ, CNTB, ACOG, IPHA, and AIFC

How does Rein Therapeutics compare to Equillium?

Which has more risk and volatility, RNTX or EQ?

Which has better earnings and valuation, RNTX or EQ?

Is RNTX or EQ more profitable?

Does the media prefer RNTX or EQ?

Do institutionals & insiders believe in RNTX or EQ?

Do analysts rate RNTX or EQ?

Summary

How does Rein Therapeutics compare to Connect Biopharma?

Which has more risk and volatility, CNTB or RNTX?

Which has stronger valuation and earnings, CNTB or RNTX?

Is CNTB or RNTX more profitable?

Does the media favor CNTB or RNTX?

Do insiders and institutionals believe in CNTB or RNTX?

Do analysts prefer CNTB or RNTX?

Summary

How does Rein Therapeutics compare to Alpha Cognition?

Do institutionals and insiders believe in RNTX or ACOG?

Do analysts prefer RNTX or ACOG?

Which has preferable valuation & earnings, RNTX or ACOG?

Is RNTX or ACOG more profitable?

Does the media refer more to RNTX or ACOG?

Which has more volatility & risk, RNTX or ACOG?

Summary

How does Rein Therapeutics compare to Innate Pharma?

Do analysts prefer RNTX or IPHA?

Do institutionals and insiders believe in RNTX or IPHA?

Which has preferable valuation & earnings, RNTX or IPHA?

Is RNTX or IPHA more profitable?

Does the media refer more to RNTX or IPHA?

Which has more volatility & risk, RNTX or IPHA?

Summary

How does Rein Therapeutics compare to ALT5 Sigma?

Which has better valuation and earnings, RNTX or AIFC?

Do analysts prefer RNTX or AIFC?

Is RNTX or AIFC more profitable?

Does the media refer more to RNTX or AIFC?

Do insiders & institutionals believe in RNTX or AIFC?

Which has more risk & volatility, RNTX or AIFC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX vs. The Competition

Rein Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools